ORTHOINDY

• Theradaptive's OsteoAdapt SP clinical trial expands to include anterior lumbar interbody fusion (ALIF) and lateral lumbar interbody fusion (LLIF) procedures, alongside the existing transforaminal interbody fusion (TLIF) approach. • The FDA approved expansion triples the number of investigational sites in the U.S., facilitating broader patient access to the study of this novel therapy for degenerative disc disease. • OsteoAdapt SP combines a modified bone morphogenetic protein-2 (BMP-2) with a synthetic bone graft, aiming to enhance bone formation while minimizing off-target effects compared to traditional BMP-2. • Enrollment for ALIF and LLIF study participants is expected to commence in early 2025, potentially accelerating the path to market for this investigational biologic.

Theradaptive's OsteoAdapt SP Spinal Fusion Trial Expands to ALIF and LLIF Procedures